Recent Updates — BCYC

Bicycle Therapeutics reported a third-quarter 2026 net loss of $10.5 million, or $(0.15) basic and diluted loss per share, compared to a $59.1 million loss in the prior-year period. The company held $469.9 million in cash and cash equivalents as of September 30, 2026, with an expected cash runway extending into 2030. Collaboration revenue increased to $34.1 million from $11.7 million due to the recognition of remaining revenue upon the termination of a collaboration agreement with Bayer Consumer Care AG. Research and development expenses decreased to $33.4 million from $58.4 million, primarily driven by workforce reductions and lower clinical program costs. The company also announced that nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing novel bicyclic peptide therapeutics.

Bicycle Therapeutics plc reported financial results for the second quarter ended June 30, 2026. The company posted a net loss of $50.3 million, or $(0.72) per share, compared to a net loss of $79.0 million in the prior year period. Research and development expenses decreased to $41.2 million from $71.0 million, primarily due to lower clinical program costs for zelenectide and workforce reductions announced in March 2026. General and administrative expenses fell to $14.0 million from $18.5 million. Cash and cash equivalents stood at $510.1 million as of June 30, 2026, with an expected runway into 2030. The company presented new clinical data for nuzefatide pevedotin in pancreatic cancer and zelenectide pevedotin in urothelial cancer at the AACR and ASCO meetings, respectively. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing novel bicyclic peptide therapeutics for oncology.